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Abstract
Background—Published findings indicate that acetaldehyde (ACD; the first metabolite of 
EtOH) and salsolinol (SAL; formed through the non-enzymatic condensation of ACD and 
dopamine) can be formed following ethanol (EtOH) consumption. Both ACD and SAL exhibit 
reinforcing properties within the posterior ventral tegmental area (pVTA) and both exhibit an 
inverted “U-shaped” dose-response curve. The current study was undertaken to examine the dose-
response effects of microinjections of ACD or SAL into the pVTA on DA efflux in the nucleus 
accumbens shell (AcbSh).
Methods—For the first experiment, separate groups of male Wistar rats received pulse 
microinjections of aCSF or 12, 23 or 90 µM ACD into the pVTA while extracellular DA levels 
were concurrently measured in the AcbSh. The second experiment was similarly conducted, 
except rats were given microinjections of aCSF or 0.03, 0.3, 1.0 or 3.0 µM SAL, while 
extracellular levels of DA were measured in the AcbSh.
Results—Both ACD and SAL produced a dose-dependent inverted “U-shaped” response on DA 
release in the AcbSh, with 23 µM ACD (200% baseline) and 0.3 µM SAL (300% baseline) 
producing maximal peak responses with higher concentrations of ACD (90 µM) and SAL (3.0 
µM) producing significantly lower DA efflux.
Conclusions—The findings from the current study indicate that local application of 
intermediate concentrations of ACD and SAL stimulated DA neurons in the pVTA, whereas 
higher concentrations may be having secondary effects within the pVTA that inhibit DA neuronal 
activity. The present results parallel studies on the reinforcing effects of ACD and SAL in the 
pVTA and support the idea that the reinforcing effects of ACD and SAL within the pVTA are 
mediated by activating DA neurons.
Keywords
Acetaldehyde; Salsolinol; Dopamine; Posterior Ventral Tegmental Area; Nucleus Accumbens 
Shell
Send Correspondence to: Gerald A Deehan Jr., Indiana University School of Medicine, Institute of Psychiatric Research, 791 Union 
Drive, Indianapolis, IN 46202, gdeehan@iupui.edu, Phone: +001-317-274-8680, Fax: +001-317-274-1365. 
None of the authors has a conflict of interest associated with this research.
NIH Public Access
Author Manuscript
Alcohol Clin Exp Res. Author manuscript; available in PMC 2014 December 14.
Published in final edited form as:
Alcohol Clin Exp Res. 2013 May ; 37(5): 722–729. doi:10.1111/acer.12034.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Introduction
Acetaldehyde (ACD) and salsolinol (SAL) are two biologically active compounds that can 
be formed following the consumption of ethanol (EtOH). ACD is the first metabolite of 
EtOH and is formed in the brain mainly through a catalase-mediated reaction (Jamal et al., 
2007). SAL, on the other hand, can be formed in the brain through the non-enzymatic 
condensation of ACD and dopamine (DA) (Melchior and Collins, 1982). Over the past four 
decades, several studies have suggested that ACD and SAL may have significant roles in the 
behavioral and neurobiological effects of EtOH, and the development of EtOH abuse and 
alcoholism (for review see: Deehan et al., 2012).
In rats, ACD has been found to increase the consumption of EtOH (Brown et al., 1980; 
Myers et al., 1984b; Tampier & Quintanilla, 2002), as well as produce a conditioned place 
preference following both central and peripheral administration (Peana et al., 2008; 
Quintanilla & Tampier, 2003; Smith et al., 1984). Rats will readily self-administer ACD 
intravenously (Myers et al., 1984b), as well as into the lateral ventricle (Amit et al., 1977; 
Brown et al., 1980). SAL appears to be reinforcing in rats to a similar extent, as 
microinjections of SAL or tetrahydropapaveroline (THP; formed via the condensation of DA 
and dopaldehyde) into the lateral ventricle produce enduring increases in EtOH intake and 
preference (Duncan & Deitrich, 1980; Myers & Melchior, 1977). Further, rats will exhibit a 
conditioned place preference following SAL exposure (Hipolito et al., 2011).
Several studies, utilizing pharmacological agents capable of inhibiting brain catalase activity 
(Aragon & Amit 1992; Koechling & Amit 1994; Aragon et al., 1985, 1989; Escarabajal et 
al., 2000; Karahanian et al., 2011) or sequestering aldehydes (Font et al., 2005, 2006a,b; 
Peana et al., 2008), have suggested that some of the behavioral and pharmacological effects 
of EtOH can be attributed to the formation of ACD. Additionally, compelling evidence for 
the involvement ACD in the central actions of EtOH comes from data generated through the 
use of lentiviral vectors. Administration of a lentiviral vector that inhibits the formation of 
catalase synthesis within the VTA decreased both the voluntary consumption of EtOH as 
well as EtOH stimulated DA release (Karahanian et al., 2011; Quintanilla et al., 2012). 
While the formation of SAL may not be directly altered by the aforementioned 
manipulations, suppression of the formation of ACD would subsequently result in the 
suppression of the formation of SAL.
Behavioral data indicate that both ACD and SAL exhibit potent reinforcing properties 
within the mesolimbic DA reward pathway. Utilization of the intracranial self-
administration (ICSA) paradigm, whereby rats receive response contingent infusions of a 
compound directly into a discrete brain region, established that rats will readily self-
administer both ACD and SAL directly into the pVTA (Rodd et al., 2005; 2008). It appears 
that the pVTA is significantly more sensitive to the reinforcing properties of both ACD and 
SAL compared to EtOH. Alcohol-preferring (P) rats display the highest levels of ICSA for 
23 µM ACD and 0.1 µM SAL, doses that are approximately 2,000 fold and 400,000 fold 
lower than the optimum dose of EtOH (200 mg%; 44 mM), respectively (Rodd et al., 2005, 
2008; Rodd-Henricks et al., 2002). Responding/infusion data from the ICSA experiments 
exhibit an inverted “U-shaped” dose response curve for both ACD and SAL, in which lower 
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and higher doses do not produce reliable responding/self-infusions (Rodd et al., 2005, 2008; 
Rodd-Henricks et al., 2002). Pharmacological manipulations suggest that the reinforcing 
effects of both ACD and SAL within the pVTA appear to involve the activation of DA 
neurons (Rodd et al., 2005; 2008). This is further supported by neurobiological data showing 
that ACD and/or SAL stimulate DA neurons within the pVTA (Melis et al., 2009; Xie et al., 
2012)
To date, the limited research completed on the effect of the local administration of ACD or 
SAL within the pVTA on DA efflux within the AcbSh suggests that both compounds act to 
increase DA efflux. Melis et al. (2007) reported that the reverse microdialysis of 75 uM 
ACD in the pVTA produced an increase in DA release in the AcbSh to 150% that of 
baseline. A microinjection of 150 uM SAL into the pVTA increased DA levels in the AcbSh 
to 130% of baseline (Hipolito et al., 2011). However, the literature lacks an adequate 
examination of a dose response for both ACD and SAL at a range of pharmacologically 
relevant concentrations that have been shown to be reinforcing/rewarding (Rodd et al., 2003; 
2008) as well as stimulate DA neuronal activity (Xie et al., 2012) within the pVTA. 
Therefore, the current study was designed to examine the DA stimulatory properties of both 
ACD and SAL on the projection from the pVTA to the AcbSh for the range of 
concentrations observed to exhibit an inverted “U-shaped” dose response curve during ICSA 
testing (Rodd et al., 2005; Rodd-Henricks et al., 2002). The hypothesis of the current study 
is that microinjections of ACD or SAL into the pVTA will dose-dependently alter DA efflux 
in the AcbSh in a manner consistent with previous ICSA observations. Specifically, doses of 
either compound that fall within the middle of the dose range will produce the largest 
increases in DA release with lower and higher doses producing significantly smaller or 
negligible changes in DA efflux.
Methods
Animals
Male adult Wistar rats (weight 350 to 400 g, Harlan, Indianapolis, IN) were used in this 
study. All rats were housed 2 per cage in a temperature and humidity controlled colony 
room. Rats were maintained on a reverse 12 h light/12 h dark schedule (lights on at 0700). 
Food and water were available ad libitum except during habituation and the microdialysis 
session. All protocols were reviewed and approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee. All experimental procedures were 
in accordance with the principles outlined in the Guide for the Care and Use of Laboratory 
Animals (National Research Council, 1996).
General stereotaxic surgery procedures
While under 2% isoflurane inhalation anesthesia, all rats were implanted ipsilaterally with 
two guide cannula (Plastics One, Inc., Roanoke, VA, USA) aimed approximately 1.0 mm 
above their respective target region. A 22 gauge guide cannula targeted the pVTA (AP −5.6 
mm, ML +2.1 mm, DV −8.5 mm) while an 18 gauge cannula targeted the AcbSh (AP +1.7 
mm, ML +2.3 mm, DV −5.4 mm; Paxinos and Watson, 2005). Both cannula were implanted 
at a 10° angle from the vertical. Dummy stylets were inserted into the cannula immediately 
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following surgery and remained in place until the start of experimental procedures. 
Following surgery, all rats were housed singly and provided 7 days to recover prior to the 
start of testing. During the final 3 days of recovery, all rats underwent daily handling and 
habituation to the microdialysis chambers. On the final recovery day, loop style 
microdialysis probes (active length 2.0 mm, Spectra/Por RC, inner diameter 200 µm, 
molecular weight cut-off: 13,000, Spectrum laboratories, Inc, Rancho Dominguez, CA) were 
inserted into the AcbSh following handling/habituation.
EMIT System
The electrolytic microinfusion transducer (EMIT) system has been previously used in this 
laboratory, as well as other laboratories to identify the neuroanatomical substrates that 
underlie the reinforcing properties of many drugs of abuse (McBride et al., 1999). The 
EMIT system used in the current study is identical to that described previously (Ding et al., 
2009a).
Chemical Agents for Microinjections
ACD (Sigma-Aldrich, St. Louis, MO) was dissolved in artificial cerebrospinal fluid (aCSF) 
that consisted of 120 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2mM MgSO4, 25mM 
NaHCO3, 2.5 mM CaCl, and 10 mM d-glucose and the pH was adjusted to 7.4 ± 0.1. To 
minimize the oxidation of SAL (Sigma-Aldrich, St. Louis, MO), 0.2 ascorbate was added to 
the aCSF solution described above and the pH of all SAL solutions as well as the aCSF 
solution were adjusted to 6.5 ± 0.1. All ACD and SAL solutions were protected from light 
and maintained on ice until transfer into the microinjector reservoir.
General Microinjection/Microdialysis Procedure
Approximately 16 to 18 hrs prior to testing, microdialysis probes were inserted into the 
AcbSh. The general procedures used for the current experiments have been previously 
described (Ding et al., 2009a). Briefly, rats were placed in Plexiglass chambers (40 cm X 28 
cm X 40 cm) and connected to a Harvard pump using PE20 tubing (inner diameter 0.38 mm; 
Becton Dickinson & Co., MD). Microdialysis aCSF (140.0 mM NaCl, 3.0 mM KCl, 1.2 mM 
CaCl2, 2.0 mM Na2HPO47H2O, 1.0 mM MgCl2, pH 7.2 to 7.4) was perfused through the 
dialysis probes at a flow rate of 1.0 µl/min. Following an initial 90-min washout period, four 
to five 20-min baseline samples were taken before rats received microinjections of ACD 
(12, 23, or 90 µM), SAL (0.03, 0.3, 1.0, or 3.0 µM), or aCSF. Each microinjection was 
administered at a volume of 100 nl over a 5-sec period. Microinjections were given at a rate 
of 3 microinjections per min with one microinjection every 20 sec (30 microinjections, 3 µl 
of test solution total per subject) during the first 10 min of sample 5 or 6. An additional five 
20-min samples were collected following the microinjections. Lag time from the 
microdialysis probe outlet was approximately 20 min and was accounted for in all analyses. 
Samples were collected in microfuge vials which contained 5 µl of perchloric acid (0.1 N), 
then frozen immediately on dry ice and stored at −70°C.
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Sample Analysis
Dialysate samples were analyzed for DA levels using a reversed-phase high pressure liquid 
chromatography (HPLC) system with electrochemical detection as previously described by 
Engleman et al., (2006).
Histology
Immediately following microdialysis testing, rats were sacrificed with an overdose of CO2 
inhalation. Bromophenol blue (1%; 0.5 µl) was then injected into the pVTA as well as 
perfused through the dialysis probe in the AcbSh. Brains were rapidly removed and frozen 
on dry ice and then stored at −70°C. Brains were sectioned (40 µm) using a cryostat 
microtome. All sections were stained with cresyl violet and examined with a light 
microscope for verification of placement of both the injector and microdialysis sites using 
the rat brain atlas of Paxinos and Watson (2005).
Statistical Analysis
Data for the current study were normalized by taking the final 3 baseline microdialysis 
samples prior to microinjections, averaging them, and presenting the data as a percent of this 
baseline value. The normalized data were then analyzed using a 4 × 8 and a 5 × 8 
(Concentration × Sample) mixed analyses of variance (ANOVA) for the ACD and SAL 
groups, respectively. When significant effects (p<0.05) were observed using the mixed 
ANOVA’s, post hoc Tukey’s b or Student’s t-tests were utilized to determine differences 
between specific drug concentrations and across the time course of sample collection. All 
analyses were conducted using SPSS® 17.0 for windows.
Results
The effect of ACD microinjections into the pVTA on DA efflux in the AcbSh
Figure 1 represents the histological placements of the microdialysis cannula in the AcbSh 
(panel A, left hemisphere) and the injection cannula in the pVTA (panel B, left hemisphere). 
Approximately 7 rats had cannula placements outside these target brain areas and were 
excluded from analyses. The data in Figure 2 (left panel) were analyzed with a 4 × 8 
(Concentration × Sample) mixed ANOVA which revealed a significant effect of 
concentration (F3,22 = 10.85; p<0.05), of sample (F7,154 = 8.02; p<0.05) and a significant 
concentration by sample interaction (F21,154 = 4.36; p<0.05). Further analysis of the main 
effects via a Tukey’s b post hoc analysis found that microinjections of 23 µM ACD into the 
pVTA significantly increased DA efflux in the AcbSh compared to all other groups tested 
(p<0.05). The data in Figure 2 (right panel) represent the results of an area under the curve 
(AUC) analysis. A series of pairwise comparisons revealed similar findings to that of the 
ANOVA as the 23 µM ACD group possessed a significantly higher mean AUC than all 
other groups (p<0.05). Additionally, AUC for the 90 µM ACD group was significantly 
greater than that for the aCSF group (p<0.05).
To break down the significant concentration × sample interaction, a series of one-way 
ANOVA’s were performed, with Tukey’s b post hoc tests when justified, on each post-
injection sample to provide a greater resolution as to group differences at each discrete time 
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point. To simplify the presentation of the statistical data, one-way ANOVA’s for all post-
injection samples exhibited a significant effect of concentration (F’s > 3.91; p’s<.05). Post 
hoc analysis for sample 4 (the first post-injection sample) identified that this effect was 
driven by a significantly higher level of DA exhibited by the 23 µM and 90 µM groups 
compared to the aCSF and 12 µM groups (p<0.05) and aCSF group (p<0.05), respectively. 
For sample 5, post hoc analysis indicated that the 23 µM group had a significantly higher 
DA level than all other groups (p<0.05) and the DA level measured in the 90 µM group 
significantly exceeded that of the aCSF group (p<0.05). Similar results were observed for 
sample 6 as the 23 µM group once again exhibited a significantly higher level of DA efflux 
compared to all of the other groups (p<0.05) and the 90 µM group exhibited a significantly 
greater DA release than the 12 µM group (p<0.05). For both samples 7 and 8, statistical 
analysis revealed a significantly higher DA level in the 23 µM group compared to all other 
groups (p<0.05) with no other group differences present.
The effect of SAL microinjections into the pVTA on DA efflux in the AcbSh
Figure 1 shows the representative histological placements in the AcbSh (panel A, right 
hemisphere) and pVTA (panel B, right hemisphere). A total of 6 animals had placements 
outside of the AcbSh or the pVTA and were excluded from analyses. Pulse microinjections 
of SAL into the pVTA dose-dependently altered DA efflux in the AcbSh. As displayed in 
Figure 3 (left panel), a 5 × 8 (concentration × sample) mixed ANOVA indicated a 
significant effect of concentration (F4,31 = 10.318; p<0.05), sample (F7,217 = 14.50; p<0.05) 
and a significant concentration × sample interaction (F28,217 = 3.74; p<0.05). Post hoc 
comparisons using the Tukey’s b test revealed that local administration of the 0.3 µM dose 
of SAL in the pVTA produced a significantly higher level of DA efflux in the AcbSh 
compared to any other treatment group (p<0.05). Additionally, the 1.0 µM dose of SAL 
produced a significantly higher amount of DA release than aCSF only (p<0.05). An 
additional investigation of the data using AUC analysis revealed similar findings (see Figure 
3, right panel). Pairwise comparisons found that the mean AUC of the 0.3 µM SAL group 
significantly exceeded all other groups (p<0.05). The mean AUC for the 1.0 µM and 3.0 µM 
SAL groups were significantly greater than the aCSF and 0.03 µM SAL groups (p<0.05) but 
did not significantly differ from one another.
In order to tease apart the concentration × sample interaction, separate one-way ANOVA’s 
with post hoc analyses were completed to compare all five groups at each post-injection 
sample in an identical fashion to that described for experiment 1. For the first post-injection 
sample, there was a significant effect of drug concentration (F4,31 = 6.03; p<0.05), as the 0.3 
µM, 1.0 µM, and 3.0 µM groups exhibited significantly higher levels of DA compared to the 
aCSF and 0.03 µM groups (p<0.05). Similarly, on the second post-injection sample, a one-
way ANOVA observed a significant effect of concentration (F4,31 = 10.65; p<0.05). 
However, the post hoc test indicated that this effect was driven by the 0.3 µM SAL group, as 
it displayed a significantly elevated level of DA compared to all other groups (p<0.05) with 
no other group differences present. One-way ANOVA’s performed on the final three 
samples did not yield any significant effects of concentration (F’s < 2.14; p’s>0.63).
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Discussion
The present findings support the hypothesis that local administration of ACD or SAL within 
the pVTA produced an inverted “U-shaped” dose response curve for DA release within the 
AcbSh. The 23 µM dose of ACD produced the maximal increase in DA efflux to 200% of 
baseline level. Thus, it appears that ACD acts on DA neurons projecting to AcbSh, in a 
manner that has been described to underlie the addictive properties of virtually every major 
drug of abuse, including EtOH (for review see: Willuhn et al., 2010). This finding is in line 
with accumulating data that implicate the DA reward pathway as a primary mechanism 
underlying the rewarding properties of ACD (for review see: Deehan et al., 2012). Further, 
ACD appears to be significantly more potent than EtOH with regard to the stimulation of 
DA release. Ding et al (2009a) reported that 200 mg% (44 mM) EtOH microinjected into the 
VTA of EtOH naïve Wistar rats produced the greatest increase in DA efflux (150% of 
baseline), whereas the optimal dose of ACD (23 µM) was over 1800 fold lower, producing a 
higher DA efflux (200% of baseline). A similar observation has been reported using the 
ICSA paradigm, as alcohol-preferring (P) rats exhibited a similar dose response curve, in 
which 23 µM ACD and 150 mg% EtOH represented the optimal doses that were self-
administered into the VTA (Rodd et al., 2005). Moreover, it was demonstrated that the 
ICSA of both EtOH and ACD were significantly decreased by the co-infusion of the DA D2 
receptor agonist quinpirole (Rodd et al., 2005). Thus, the current data offer further support 
that the rewarding properties of ACD are a function of activation of DA neurons within the 
pVTA.
The present data also support the hypothesis that microinjections of SAL into the pVTA 
would increase DA efflux in the AcbSh. The dose-response curve indicated that the optimal 
dose of SAL (0.3 µM) stimulated extracellular DA levels within the AcbSh to 300% of 
baseline. Thus, the data indicate that SAL is capable of stimulating DA neuronal activity 
within the pVTA. This finding compliments previous research showing that the reinforcing 
properties of SAL in the VTA is dependent on DA signaling (Rodd et al., 2008), and 
provides further evidence that SAL is highly efficacious at stimulating DA release at low 
doses. Thus, the current findings, along with past research (Rodd et al., 2008), provide 
support for the hypothesis that DA release within the AcbSh is a key mediator in the 
reinforcing properties of SAL.
The current data further elucidate the stimulatory properties of ACD and SAL on pVTA DA 
neurons. Previous experiments had reported that the reverse microdialysis of 75 µM ACD in 
the VTA increased DA release in the AcbSh to 150% of baseline (Diana et al., 2008; Melis 
et al., 2007) whereas a single microinjection of 150 µM SAL into the pVTA increased DA 
levels within the AcbSh to 130% of baseline (Hipolito et al., 2011). Even though the most 
effective concentrations in the current study (23 µM ACD and 0.3 µM SAL) were 
significantly lower (approximately 3 fold and 500 fold lower respectively), differences 
between the paradigms may be partially responsible. For example, in the case of reverse 
microdialysis of ACD, probe recoveries of 10–20% could account for the main difference in 
the effective concentrations. On the other hand, it is difficult to reconcile the 500-fold 
difference in the effective SAL concentration between the current study and the study of 
Hipolito et al. (2011), even though different microinjection and microdialysis techniques 
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were used. The 150 uM SAL concentration is much greater than the estimated levels of SAL 
in brain tissue, and may be producing secondary effects resulting in increased DA release.
It is important to note that the current data represent the first thorough report of the dose-
response for both ACD and SAL on DA release at low, pharmacologically relevant, 
concentrations that have been shown to be rewarding within the pVTA. Furthermore, the 
optimal dose of ACD, tested in experiment 1, falls within the range of pharmacologically 
relevant concentrations detected in the brain following EtOH exposure in mice (Isse et al., 
2005). Quantitative estimation of brain SAL levels following EtOH exposure has produced 
variable results; however, recent research has indicated a positive correlation between EtOH 
consumption and SAL levels in the midbrain (Rojkovicova et al., 2008). Therefore, the 
current findings offer additional support of a possible role for centrally formed ACD and/or 
SAL in contributing to the actions of EtOH.
Utilizing a range of concentrations of ACD and SAL, that were similar to concentrations 
used in the ICSA experiments, the microinjection-microdialysis results also exhibited 
inverted “U-shaped” dose-response curves similar to those observed for the reinforcing 
properties of ACD and SAL (Rodd et al., 2005; 2008). Much like the ICSA findings, 
concentrations of ACD (23 µM) and SAL (0.3 µM) that caused the maximal DA response 
within the AcbSh fell in the middle of a dose response curve in which higher and lower 
concentrations were significantly less effective. Intra-pVTA microinjections of ACD and 
SAL at concentrations higher than the optimum level (23 µM and 0.3 µM, respectively) were 
less effective at increasing DA release in the AcbSh possibly due to a number of interactions 
between the higher concentrations of ACD and SAL and several neuronal mechanisms 
which increase inhibitory and/or decrease excitatory actions on DA neurons. Observations 
from the current data also coincide with the ICSA data in that the pVTA exhibited a 
significantly greater sensitivity to SAL compared to ACD. The dose response curve for SAL 
is far lower (shifted to the left) than that of ACD; the most effective dose of SAL (0.3 µM) is 
approximately 70-fold lower than the most effective dose of ACD (23 µM). Moreover, SAL 
caused a greater amount of DA release compared to ACD, as 0.3 µM SAL stimulated a 
maximal increase in DA release to 300% of baseline, whereas 23 µM ACD stimulated a 
maximal increase to 200% of baseline, suggesting SAL may be activating more DA neurons 
in the pVTA.
The data indicated that concentrations that did not support the ICSA of SAL into the pVTA 
(i.e., 1.0 µM and 3.0 µM) still stimulated DA release in the AcbSh, although the amount of 
DA was significantly lower compared to 0.3 µM SAL (Figs. 2 & 3). The reduction in DA 
release observed at the highest concentrations may be a result of SAL having effects on one 
or more other systems within the pVTA that reduce DA neuronal activity. The observation 
that higher SAL concentrations did not produce reinforcing effects, as reported by Rodd et 
al., 2008, could be a combination of neurobiological interactions that result in reduced DA 
neuronal activity and/or other unknown actions of SAL.
In contrast to the effects observed for SAL, 12 µM ACD was within the range of 
concentrations self-administered during ICSA testing (Rodd et al., 2005) yet failed to 
significantly alter DA release (Figs. 2 & 3). One possible reason for this disagreement may 
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be due to the difference in drug exposure between the microinjection/microdialysis and 
ICSA paradigms. The microinjection/microdialysis paradigm utilized in the current study 
involved an acute exposure to ACD over a 10-min microinjection period. The ICSA 
paradigm, on the other hand, involved repeated exposure to ACD over multiple 4-hour 
sessions run every other day (Rodd et al., 2005; 2008). It is possible that sensitization to the 
reinforcing properties of ACD may develop during the repeated exposure inherent in the 
ICSA paradigm, in effect shifting the dose response curve to the left for ACD. A similar 
argument could be used to explain why a lower dose of SAL (0.03 µM) was self-infused into 
the pVTA but had little effect on DA release when microinjected into the pVTA. 
Nonetheless, the current research shows that microinjections of ACD and SAL into the 
pVTA stimulate DA release in the AcbSh at concentrations that have been found to support 
the ICSA of both compounds.
There are likely several neurobiological mechanisms that contribute to the observed 
stimulation of DA release resulting from the local administration of ACD and SAL within 
the pVTA. Research has implicated the mu opioid receptor (MOR) as a prime candidate for 
the rewarding aspects of both ACD and SAL as naloxone significantly decreased IV self-
administration of ACD (Myers et al., 1984a), whereas naltrexone and β-funaltrexamine (a 
selective MOR antagonist) microinjected directly into the VTA blocked ACD and SAL 
induced locomotor activity (Hipolito et al., 2010; Matsuzawa et al., 2000; Sanchez-Catalan 
et al., 2009). Recently, electrophysiological data indicate SAL indirectly stimulates DA 
neurons within the pVTA through action at MORs on gamma-aminobutryric acid (GABA) 
at concentrations tested in the current study (Xie et al., 2012). Thus, it can be speculated that 
MORs within the mesolimbic system are likely a contributory mechanism underlying the 
rewarding/reinforcing action of ACD and/or SAL.
In conclusion, various laboratories have suggested that the reinforcing/rewarding properties 
of both ACD and SAL are mediated, in part, by the DA system. However, a limited amount 
of the research thus far has administered both ACD and SAL centrally and investigated how 
DA signaling is altered. The current study represents the first thorough investigation of the 
stimulatory properties of both ACD and SAL within the pVTA, and the subsequent DA 
release within the AcbSh. The data from these experiments show that both ACD and SAL 
are capable of stimulating dopaminergic activity within the reward pathway at low 
concentrations. Moreover, data from the current research indicate that both ACD and SAL 
stimulate the DA projection from the VTA to the AcbSh in a manner similar to several drugs 
of abuse. While the exact extent to which ACD and SAL are involved in the rewarding 
properties of alcohol remains to be resolved, it will be beneficial for future research to focus 
on elucidating this relationship which, in turn, may help with the development of novel 
pharmacotherapies and treatments for individuals suffering from alcohol use disorders.
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Figure 1. 
Represents the histological placements of the microdialysis cannula in the AcbSh (panel A) 
and the microinjection cannula in the posterior VTA (panel B) for Experiments 1 and 2. 
Placements for Experiment 1 are presented in the left hemisphere while placements for 
Experiment 2 are presented in the right hemisphere. Animals with cannula outside of these 
target brain regions were excluded from analyses. Histological plates have been adapted 
from Paxinos and Watson (2006).
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Figure 2. 
Dose-response effects of microinjections of ACD into the pVTA on DA efflux in the AcbSh. 
Microdialysis time-course data (left panel) are presented as means (± SEMs) percent 
baseline levels. Bar indicates microinjection period, microinjections were given 3 times a 
min over the first 10 min of sample 3. The area under the curve data is presented as means 
(± SEMs) area under the curve (right panel). * 23 µM ACD (n = 6) significantly greater (p < 
0.05) than all other groups, ^ 90 µM (n = 7) ACD significantly greater (p < 0.05) than aCSF 
group (n = 6), + 90 µM ACD significantly greater (p < 0.05) than 12 µM ACD (n = 7).
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Figure 3. 
Dose-response effects of microinjections of SAL into the pVTA on extracellular levels of 
DA in the AcbSh. Microdialysis time-course data (left panel) are presented as means (± 
SEMs) percent baseline levels. Bar indicates microinjection period, microinjections were 
given 3 times a min over the first 10 min of sample 3. Area under the curve (AUC) data 
(right panel) are presented as means (± SEMs) area under the curve. * 0.3 µM SAL (n = 6) 
significantly greater (p < 0.05) than all other groups, ^ 3.0 (n = 5), 1.0 (n = 8), and 0.3 µM 
SAL treatment groups significantly greater (p < 0.05) than 0.03 µM SAL (n = 8) and aCSF 
(n = 7) groups, + mean area under the curve for 1.0 and 3.0 µM SAL groups significantly 
greater than 0.03 and aCSF groups (p < 0.05).
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